Pharma · Private company
Chugai Pharmaceutical
Track this companyFree. Adds Chugai Pharmaceutical to your Dealase workspace and tells you when its record changes.
Clinical trials2519 recruiting or active
Pipeline programs14From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline14
- DONQ52Phase 2 · Celiac DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Simulated Inadvertent Gluten Exposure (SIGE) capsulePhase 2 · Celiac DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- AQUA07Phase 1 · ALK Positive Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- AtezolizumabPhase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- AUBE00Phase 1 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- CetuximabPhase 1 · Locally Advanced or Metastatic Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- CetuximabPhase 1 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- LorlatinibPhase 1 · ALK Positive Non-small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- LUNA18Phase 1 · Locally Advanced or Metastatic Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- RAY121Phase 1 · Antiphospholipid Syndrome (APS)ClinicalTrials.gov · fetched Nov 12, 2026
- ROSE12Phase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- SAIL66Phase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- SPYK04Phase 1 · Locally Advanced or Metastatic Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- A Study to Assess the Efficacy and Safety of Subcutaneous Induction Therapy With Afimkibart in Participants With Moderately to Severely Active Ulcerative ColitisPHASE3 · RECRUITING · started Nov 15, 2026ClinicalTrials.gov NCT07846683 · fetched Nov 12, 2026
- AQUA07 in Patients With ALK-Positive Non-Small Cell Lung CancerPHASE1 · RECRUITING · started Jul 24, 2026ClinicalTrials.gov NCT07617337 · fetched Nov 12, 2026
- A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia APHASE3 · RECRUITING · started May 15, 2026ClinicalTrials.gov NCT07416526 · fetched Nov 12, 2026
- A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia APHASE3 · RECRUITING · started Apr 27, 2026ClinicalTrials.gov NCT07416604 · fetched Nov 12, 2026
- Study of DONQ52 in Active Celiac DiseasePHASE2 · RECRUITING · started Dec 16, 2025ClinicalTrials.gov NCT07239336 · fetched Nov 12, 2026
- A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerPHASE3 · RECRUITING · started Oct 24, 2025ClinicalTrials.gov NCT06793215 · fetched Nov 12, 2026
- Study of AUBE00 in Patients With Solid TumorsPHASE1 · RECRUITING · started Jun 5, 2025ClinicalTrials.gov NCT07030959 · fetched Nov 12, 2026
- A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's DiseasePHASE3 · RECRUITING · started May 12, 2025ClinicalTrials.gov NCT06819891 · fetched Nov 12, 2026
- A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's DiseasePHASE3 · RECRUITING · started Mar 17, 2025ClinicalTrials.gov NCT06819878 · fetched Nov 12, 2026
- A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung CancerPHASE3 · ACTIVE_NOT_RECRUITING · started Sep 23, 2024ClinicalTrials.gov NCT06497556 · fetched Nov 12, 2026
- A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative ColitisPHASE3 · ACTIVE_NOT_RECRUITING · started Sep 17, 2024ClinicalTrials.gov NCT06589986 · fetched Nov 12, 2026
- Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)PHASE1 · RECRUITING · started Aug 19, 2024ClinicalTrials.gov NCT06371417 · fetched Nov 12, 2026
- A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010PHASE1 · COMPLETED · started Oct 2, 2023ClinicalTrials.gov NCT05867121 · fetched Nov 12, 2026
- A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)PHASE3 · ACTIVE_NOT_RECRUITING · started Sep 14, 2023ClinicalTrials.gov NCT05904886 · fetched Nov 12, 2026
- A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid TumorsPHASE1 · RECRUITING · started May 24, 2023ClinicalTrials.gov NCT05907980 · fetched Nov 12, 2026
- A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid TumorsPHASE1 · COMPLETED · started Apr 17, 2023ClinicalTrials.gov NCT05735366 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) EncephalitisPHASE3 · ACTIVE_NOT_RECRUITING · started Sep 27, 2022ClinicalTrials.gov NCT05503264 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated DiseasePHASE3 · ACTIVE_NOT_RECRUITING · started Aug 30, 2022ClinicalTrials.gov NCT05271409 · fetched Nov 12, 2026
- A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)PHASE3 · ACTIVE_NOT_RECRUITING · started Nov 17, 2021ClinicalTrials.gov NCT04958265 · fetched Nov 12, 2026
- A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)PHASE3 · ACTIVE_NOT_RECRUITING · started Oct 22, 2021ClinicalTrials.gov NCT04861259 · fetched Nov 12, 2026
- A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia GravisPHASE3 · TERMINATED · started Oct 19, 2021ClinicalTrials.gov NCT04963270 · fetched Nov 12, 2026
- A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).PHASE1 · TERMINATED · started Oct 8, 2021ClinicalTrials.gov NCT05012618 · fetched Nov 12, 2026
- A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement InhibitorsPHASE3 · ACTIVE_NOT_RECRUITING · started Sep 30, 2020ClinicalTrials.gov NCT04432584 · fetched Nov 12, 2026
- A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).PHASE1 · COMPLETED · started Sep 10, 2020ClinicalTrials.gov NCT04511845 · fetched Nov 12, 2026
- A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor TreatmentPHASE3 · TERMINATED · started Jul 28, 2020ClinicalTrials.gov NCT04338269 · fetched Nov 12, 2026